Shandong Pharmaceutical Glass Co.Ltd

SHSE:600529 Rapport sur les actions

Capitalisation boursière : CN¥15.8b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Shandong Pharmaceutical GlassLtd Croissance future

Future contrôle des critères 1/6

Shandong Pharmaceutical GlassLtd is forecast to grow earnings and revenue by 17.8% and 12.7% per annum respectively. EPS is expected to grow by 17.8% per annum. Return on equity is forecast to be 13.1% in 3 years.

Informations clés

17.8%

Taux de croissance des bénéfices

17.8%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices22.5%
Taux de croissance des recettes12.7%
Rendement futur des capitaux propres13.1%
Couverture par les analystes

Good

Dernière mise à jour08 Aug 2024

Mises à jour récentes de la croissance future

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

May 31
Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

May 13
The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Prévisions de croissance des bénéfices et des revenus

SHSE:600529 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20267,1181,371N/A1,5947
12/31/20256,4021,183N/A1,3739
12/31/20245,6281,000N/A1,0969
3/31/20245,0138304591,134N/A
12/31/20234,9827763761,048N/A
9/30/20234,87273882781N/A
3/31/20234,382632-99502N/A
12/31/20224,187618-458252N/A
9/30/20224,058616-277548N/A
6/30/20224,040612-112674N/A
3/31/20223,99158825773N/A
12/31/20213,875591-59750N/A
9/30/20213,921620-55676N/A
6/30/20213,703603-206551N/A
3/31/20213,592585-243445N/A
12/31/20203,42756431566N/A
9/30/20203,147532-6498N/A
6/30/20203,09350389594N/A
3/31/20203,042484-53596N/A
12/31/20192,9924597599N/A
9/30/20192,821437-87546N/A
6/30/20192,720409-31493N/A
3/31/20192,651386124492N/A
12/31/20182,585358118466N/A
9/30/20182,546326245485N/A
6/30/20182,481298237446N/A
3/31/20182,400281187349N/A
12/31/20172,330263N/A412N/A
9/30/20172,314259N/A349N/A
6/30/20172,236236N/A423N/A
3/31/20172,181216N/A461N/A
12/31/20162,057190N/A507N/A
9/30/20161,860162N/A478N/A
6/30/20161,801159N/A446N/A
3/31/20161,758152N/A465N/A
12/31/20151,723145N/A390N/A
9/30/20151,771141N/A440N/A
6/30/20151,771130N/A341N/A
3/31/20151,717127N/A293N/A
12/31/20141,691125N/A267N/A
9/30/20141,653117N/A282N/A
6/30/20141,599122N/A260N/A
3/31/20141,577121N/A286N/A
12/31/20131,545122N/A269N/A
9/30/20131,519126N/A164N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 600529's forecast earnings growth (17.8% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 600529's earnings (17.8% per year) are forecast to grow slower than the CN market (21.9% per year).

Croissance élevée des bénéfices: 600529's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: 600529's revenue (12.7% per year) is forecast to grow slower than the CN market (13.4% per year).

Croissance élevée des revenus: 600529's revenue (12.7% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 600529's Return on Equity is forecast to be low in 3 years time (13.1%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y